Last updated on December 2013

A Phase 2b Study to Evaluate the Safety and Efficacy of Elagolix in Premenopausal Women with Heavy Menstrual Bleeding Associated with Uterine Fibroids


Brief description of study

A Phase 2b Study to Evaluate the Safety and Efficacy of Elagolix in Premenopausal Women with Heavy Menstrual Bleeding Associated with Uterine Fibroids

Detailed Study Description

The objectives of this study are to assess the safety and efficacy of elagolix (ABT-620) alone and in combination with two (2) different strengths of add-back therapy (Estradiol/Norethindrone Acetate Tablets), versus placebo to reduce heavy menstrual bleeding (HMB) asociated with uterine fibroids, and to reduce fibroid volume and uterine volume in premenopausal women 18 to 51 years of age.

Clinical Study Identifier: TX137474

Find a site near you

Start Over

AdvanceMed Research

2 Princess Road, Suite J Lawrenceville, NJ USA
  Connect »